C ardiovascular complications are a major culprit in the pathogenesis of obesity and diabetes. The increased prevalence of cardiovascular complications in diabetes is attributed to the disturbed balance between increased endothelial injury and hampered endothelial repair processes. 1 Retinopathy, a blinding disease, is a major morbidity in diabetic patients. Diabetic retinopathy is initiated by hyperglycemia-induced endothelial cell injury, retinal vessel loss, and the adaptation of an inflammatory phenotype by the endothelium. Secretion of proangiogenic factors and proinflammatory cytokines from the ischemic retina lead to an exacerbated compensatory neovascularization, resulting in abnormal retinal neovascularization. 2 Hence, the primary treatment of retinopathy aims to preserve vision through the inhibition of excessive vascularization and reduction of vascular damage.
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Interestingly, endothelial dysfunction, hampered endothelial repair, and pathological neovascularization during retinopathy reflect similar molecular alterations partially related to a state of mild chronic inflammation, ie, overproduction of inflammatory cytokines and reactive oxygen species, increased leukocyte extravasations, and vascular leakage. 3
The Adipokines
The traditional role attributed to fat tissue is energy storage; however, a change in perspective has risen since the discovery of the adipokines. Advances in the biology of the adipose tissue has revealed that it is not simply an energy storing organ but also secretes a variety of molecules, termed adipokines, that affect processes beyond metabolic regulation. 4 Bioactive substances secreted by adipocytes, the adipokines, include proinflammatory cytokines, such as leptin, angiotensinogen, plasminogen activator inhibitor 1, interleukin (IL)-6, and tumor necrosis factor (TNF)␣, and could contribute to the complications of obesity and diabetes through the amplification of inflammatory responses. 5 In contrast, the adipokine adiponectin (APN) is unique in its antiinflammatory actions, and plasma levels of APN are paradoxically decreased in obese and diabetic subjects. 6 In this issue of Circulation Research, Higuchi et al 7 examined whether APN ameliorates retinopathy through the attenuation of endothelial injury, inflammation, and neovascularization. In an elegant series of experiments, Higuchi et al showed increased retinal TNF␣ expression, exacerbated retinal inflammation, and hypoxia-induced retinal vascularization in APN knockout mice compared to their wild-type counterparts, thus illustrating the modulatory role of APN in inflammation and vascularization. Adenovirus-mediated overexpression of APN, or the administration of recombinant APN, attenuated these deleterious effects in the retina, as did blockade of TNF␣. In combination, these data implicate APN as key modulator in inflammation and pathological neovascularization, and its dysregulation adds to the severe pathologies observed in obese and diabetic patients.
Adiponectin and Vascular Inflammation
Increasing evidence suggests that obesity and diabetes are closely linked to a chronic state of mild inflammation. In obese and diabetic individuals, production of proinflammatory adipokines (eg, TNF␣, IL-6) ( Figure) is increased. Paradoxically, plasma levels of APN, the antiinflammatory adipokine, are decreased in these patients, 6 which may contribute to the chronic systemic inflammatory phenotypes of these patients.
The majority of antiinflammatory actions of APN are governed through its suppression of NF-B-binding to the DNA, and hence the suppression of NF-B target genes, such as C-reactive protein, TNF␣, and IL-6. Binding of APN to its primary receptor AdipoR1 activates the AMP-activated protein kinase (AMPK) signaling pathway in vascular endothelial cells. 8 Although the precise interaction between the AMPK-and NF-B signaling pathways remains to be elucidated, convergence of the 2 pathways was shown to directly inhibit activation of NF-B. 9 APN further has a distinct antiinflammatory action in modulating the expression of the antiinflammatory cytokine IL-10 in monocytes and macrophages. Macrophages stimulated with globular APN increased activity of both extracellular signal-regulated kinase 1/2 and cAMP-protein kinase A signaling pathways, which resulted in the phosphorylation of the transcription factor CREB. Binding of CREB to the promoter region of IL-10 subsequently increases IL-10 expression. 10 The inflammation-modulatory actions of IL-10 are 2-fold; firstly it represses NF-B activity and thus further represses the production of proinflammatory cytokines. 11 Secondly, IL-10 prevents the expression of adhesion molecules on endothelial cells, limiting the leukocyte-endothelium interaction and hence prevents leukocyte extravasations. 12 A third distinct inflammation-modulatory action of APN can be found in the sequestering of proinflammatory cytokines and growth factors. APN was shown to bind various cytokines (monocyte chemoattractant protein-1, RANTES, and macrophage inflammatory protein 1␣) and growth factors (basic fibroblast growth factor, platelet-derived growth factor-BB, and HB-EGF [heparin-binding epidermal growth factor-like growth factor]) and thereby reducing their biological activity. 13, 14 Although the precise influence of APN in the bioavailability and bioactivity of such factors remains to be determined, APN may dampen inflammatory responses by sequestering these factors.
Adiponectin and Neovascularization
Inflammation facilitates vascular regeneration after ischemic damage which is regulated by inflammatory cells such as monocytes and macrophages and circulating bone marrowderived endothelial progenitor cells (EPCs). 15 In vivo, EPCs may proliferate, migrate, and differentiate into mature endothelial cells. 16 However, this previously accepted notion has changed, and vascular remodeling and tissue repair by EPCs is now considered to be governed primarily by paracrine mediators. 15 Thus, EPCs would seem ideal candidates to alleviate endothelial dysfunction and to augment neovascularization. Unfortunately, in diseases with a chronic inflammatory vascular component, such as diabetes and cardiovascular disease, numbers of circulating EPCs are severely reduced, and these EPCs are dysfunctional as well. 17 APN and other mediators that affect the lipid metabolism, such as statins, augment recruitment of EPCs from the bone marrow and may provide a therapeutic modality to increase EPCs frequency and relieve dysfunction (Figure) . In vitro, APN improves the outgrowth of EPC colonies through presently unidentified mechanisms. In accordance, APN knockout mice portray negligible EPC mobilization, which can be restored by systemic administration of APN. 18 Although Higuchi et al did not address the function of EPCs in vascular maintenance during retinopathy, 7 it would be highly interesting to investigate the influence of APN on EPCmediated amelioration of vasculopathy.
Treatment of hypertension by angiotensin II inhibitors or angiotensin-converting enzyme inhibitors dramatically increase APN plasma levels in type 2 diabetes patients. 19 Similarly, thiazolidinediones not only reduce insulin resistance in diabetics but also increase APN levels, which coincides with improved endothelial function. 20 It is tempting to assume that both antihypertensives and thiazolidinediones increase APN plasma levels, which dictates the mobilization of EPCs. APN also alleviates EPC dysfunction and thus contributes to the proangiogenic and vasculoprotective effect mediated by EPCs. 18 Finally, the matricellular nature of APN serves to modulate cell-matrix interactions and cell function. APN can sequester several proangiogenic growth factors and cytokines, while being bound to the extracellular matrix. Hence, APN may act as a powerful traffic sign that "lures" EPCs to cardiovascular lesions. Homed EPCs would receive appropriate instructions from the mediators that are sequestered on APN, although EPCs would further engage in cardiovascular regeneration. This supposition is substantiated by the accumulation of APN at sites of vascular wall injury. 21
Adiponectin and Fibrosis
Fibrosis is characterized by an accumulation of excess fibrous connective tissue. Collagen-producing cells, such as (myo)fibroblasts and smooth muscle cells, are key mediators of fibrosis. These cells can originate from circulating mesenchymal progenitors and from epithelial and endothelial cells by epithelial-mesenchymal or endothelial-mesenchymal transdifferentiation. Transforming growth factor (TGF)␤ plays a crucial role in initiating this transdifferentiation. 22 Interestingly, APN exerts antifibrotic effects partly by reducing TGF␤ signaling. 23 APN accumulates in the extracellular matrix, where it locally suppresses inflammation, oxidative stress, and fibrosis. 24 APN protects against angiotensin II-induced fibrosis, wherein the protective effect of APN is mediated by AMPK. APN-induced activation of AMPK leads to enhanced activity of peroxisome proliferatoractivated receptor (PPAR)-␣, counteracting its downregulation by angiotensin II. 25 Important downstream effects of PPAR-␣ activity include inhibition of NF-B, downregulation of NADPH oxidase, and upregulation of catalase and superoxide dismutase, effectively inhibiting the formation of reactive oxygen species and profibrotic TGF␤ signaling (Figure) . 25 Presently, thiazolidinediones are known to attenuate fibrosis and inflammation by directly activating PPAR-␥, leading to reduction of TGF␤. 26 Hence, one can speculate that thiazolidinediones additionally attenuate the fibrotic processes by increasing APN plasma levels and thus enhancing PPAR-␣ activity.
Perspectives
Taken together, APN is a key modulator in several pathologies that uses a plethora of signaling pathways to exhibit antiinflammatory and antifibrotic effects while maintaining vascular integrity (Figure) . Hence, diseases in which plasma levels of APN are disturbed, such as obesity and diabetes, show a variety of cardiovascular and fibrotic complications. Therapeutic agents that aim to increase plasma APN levels, such as recombinant APN and apolipoprotein mimics, 27 may offer a pleiotropic treatment option that can ameliorate a multitude of cardiovascular complications.
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